Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THALIDOMIDE vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Immunomodulatory and antiangiogenic action: TNF-alpha inhibitor, alters adhesion molecule expression, inhibits angiogenesis via VEGF/FGF inhibition, modulates T-cell co-stimulation and NF-κB activity.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Newly diagnosed multiple myeloma (in combination with dexamethasone),Leprosy (erythema nodosum leprosum)
Mild to moderate pain,Fever
100 mg orally once daily, preferably at bedtime to minimize sedation; maximum dose 400 mg daily for multiple myeloma or erythema nodosum leprosum.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Terminal elimination half-life is approximately 5-7 hours in healthy adults, but may be prolonged to 7-10 hours in patients with renal impairment or advanced age.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Primarily non-enzymatic hydrolysis in plasma; minor CYP2C19-mediated hydroxylation.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Thalidomide is primarily eliminated by nonenzymatic hydrolysis in plasma and tissues; renal excretion accounts for <1% of unchanged drug; metabolites are excreted renally (~90%) and fecally (~10%).
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Approximately 55-65% bound to albumin and alpha-1-acid glycoprotein.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Volume of distribution is approximately 1.2 L/kg (range 0.8-1.5 L/kg), indicating extensive distribution into body tissues.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Oral bioavailability is approximately 90-100% (absolute bioavailability).
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
No dosage adjustment required for renal impairment. Thalidomide is minimally renally excreted; however, use with caution in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Child-Pugh Class A: 100 mg daily. Child-Pugh Class B: Reduce to 50 mg daily or 100 mg every other day. Child-Pugh Class C: Not recommended due to lack of safety data.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Not approved for use in children; safety and efficacy not established. In investigational settings, 2-5 mg/kg/day orally divided every 12 hours, with a maximum of 100 mg/day.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
No specific dose adjustment, but start at low end of dosing range (50-100 mg daily) due to increased risk of sedation, constipation, and peripheral neuropathy. Monitor renal function, though no dose adjustment required.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
THALIDOMIDE IS CONTRAINDICATED IN PREGNANCY (CATEGORY X). Severe birth defects (phocomelia, other fetal anomalies) and fetal death. Must not be used by women who are pregnant or may become pregnant. Also contraindicated in sexually active women of childbearing potential unless using two reliable forms of contraception. Male patients must use latex condom during sexual contact with pregnant or childbearing-potential women. [See REMS program]
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Thromboembolism (DVT/PE) - increased risk with concurrent dexamethasone. Severe peripheral neuropathy (monitor for paresthesias). Neutropenia, thrombocytopenia. Dizziness, somnolence. Hypersensitivity reactions (angioedema, Stevens-Johnson syndrome). Bradycardia, syncope. Increased LFTs. Seizures. Amyloid deposition. Angioedema. Increases risk of hepatotoxicity. Use in renal/hepatic impairment with caution.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Pregnancy (Category X) - fetal toxicity. Women of childbearing potential not using two forms of contraception. Men not using latex condom. Hypersensitivity to thalidomide. Use with drugs that cause peripheral neuropathy. Severe neutropenia (ANC < 750/μL).
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Avoid grapefruit juice (may increase exposure). No specific food restrictions otherwise.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
Thalidomide is contraindicated in pregnancy. First trimester exposure causes severe limb defects (phocomelia, amelia), ear anomalies, ocular defects, and cardiac malformations in up to 50% of exposed fetuses. Second and third trimester exposure risks fetal growth restriction and neurodevelopmental effects. No safe trimester exists.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Thalidomide is excreted in human milk; M/P ratio is approximately 0.5. Breastfeeding is contraindicated due to potential adverse effects in the infant, including sedation and neutropenia.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
No dose adjustment studies in pregnancy exist because thalidomide is contraindicated. Pharmacokinetic changes in pregnancy (e.g., increased clearance, altered distribution) are expected but dose adjustments should not be attempted; alternative therapy must be used.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
Strict REMS program required due to teratogenicity; screen for pregnancy before and during therapy. Monitor for thromboembolism, neuropathy, and bradycardia. Dose reduction needed in renal impairment. Can cause tumor lysis syndrome in multiple myeloma.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Never use during pregnancy – can cause severe birth defects.,Women must use two reliable contraceptives and undergo monthly pregnancy tests.,Men must use condoms during sexual activity with a pregnant woman or a woman who could become pregnant.,Avoid blood donation while on therapy and for 4 weeks after stopping.,Report numbness, tingling, drowsiness, or rash immediately.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
"Thalidomide, a sedative-hypnotic with central nervous system (CNS) depressant properties, can additively enhance the CNS-depressant effects of tiagabine, an anticonvulsant that potentiates GABAergic neurotransmission. This combination increases the risk of excessive sedation, dizziness, psychomotor impairment, and respiratory depression. Patients may experience compounded neurological effects, leading to reduced alertness and increased fall risk, particularly during initiation or dose escalation."
"Thalidomide, a known central nervous system depressant, can potentiate the sedative effects of fluticasone propionate, particularly when administered at high doses or via inhalation. This additive CNS depression may lead to increased sedation, dizziness, and impairment of cognitive or motor function, posing risks for falls or accidents. Patients should be warned against driving or operating heavy machinery until the combined effects are known."
"Thalidomide, an immunomodulatory agent, may antagonize the laxative effect of picosulfuric acid by reducing gastrointestinal motility through its anticholinergic-like properties and potential to cause constipation. This interaction could lead to decreased effectiveness of picosulfuric acid in promoting bowel evacuation, potentially resulting in inadequate bowel preparation for procedures or incomplete relief of constipation. Clinically, patients may experience reduced stool output or delayed onset of action, requiring alternative or additional laxative therapy."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THALIDOMIDE vs ACEPHEN, answered by our medical review team.
THALIDOMIDE is a Immunomodulatory Agent that works by Immunomodulatory and antiangiogenic action: TNF-alpha inhibitor, alters adhesion molecule expression, inhibits angiogenesis via VEGF/FGF inhibition, modulates T-cell co-stimulation and NF-κB activity.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THALIDOMIDE and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THALIDOMIDE is: 100 mg orally once daily, preferably at bedtime to minimize sedation; maximum dose 400 mg daily for multiple myeloma or erythema nodosum leprosum.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THALIDOMIDE and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THALIDOMIDE is classified as Category D/X. Thalidomide is contraindicated in pregnancy. First trimester exposure causes severe limb defects (phocomelia, amelia), ear anomalies, ocular defects, and cardiac malformations in u. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.